Repurchase nearly HK$17 million in a single day! YIDU TECH (02158) significantly increases buyback efforts with accumulated repurchase amount close to HK$93 million since 2026.

On March 2nd, YIDU TECH (02158) announced a stock repurchase program, repurchasing over 2.89 million shares at a price of approximately HK$5.78 per share on the same day, with a total expenditure of nearly HK$17 million. The amount of repurchase on that day significantly increased compared to before, reflecting the management's strong confidence in the company's value and significantly enhancing confidence in the stock price. Since starting the first repurchase of the year 2026 on January 26th, YIDU TECH has been actively repurchasing shares for multiple consecutive trading days, with a total of 20 repurchase instances and total expenditure of nearly HK$93 million. This frequent and fast-paced capital action continues to send positive signals to the market. In terms of news, YIDU TECH has received positive evaluations from several mainstream institutions recently. Citigroup issued a research report, maintaining a "buy" rating on the company and raising the target price to HK$11, demonstrating a strong confidence in the company's fundamentals and long-term growth potential. At the same time, in the latest industry report, Zhonghang Securities pointed out that AI is evolving from a "technical support" role in the medical industry to becoming a core force driving "value reshaping" and "efficiency revolution," with its commercial value penetrating from the research and development end to the clinical, payment, and patient ends. Among the six investment themes, Zhonghang Securities explicitly categorizes YIDU TECH as a technology/data platform enterprise, alongside iFLYTEK Healthcare, as a key focus target, further confirming the company's key position and industry-leading position in the AI medical infrastructure field. On the business front, YIDU TECH's innovation achievements are landing intensively: the intelligent clinical evidence-based platform "MediSmart" for doctors is undergoing internal testing in an orderly manner, and the infectious disease monitoring and early warning project supported by the company's core technology in the Hainan Free Trade Port was selected for the "2025 'Data Element ' Competition National Final Winning Project Case Collection," receiving national-level recognition.